Xencor to receive $105M from Alexion in Ultomiris royalty settlement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Xencor to receive $105M from Alexion in Ultomiris royalty settlement

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

July 29, 2026 4:01 PM EDT

-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties --

-- Ex-U.S. royalties remain unchanged --

PASADENA, Calif.--(BUSINESS WIRE)--

Xencor, Inc. (NASDAQ: XNCR) (Xencor), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company (Alexion), to resolve a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz) (the Settlement Agreement).

Under the Settlement Agreement, Xencor will receive $105 million in two equal... More